Download or read book Resistance of Cancer Cells to CTL Mediated Immunotherapy written by Benjamin Bonavida and published by Springer. This book was released on 2015-06-20 with total page 364 pages. Available in PDF, EPUB and Kindle. Book excerpt: This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more.
Download or read book Immunotherapy in Resistant Cancer From the Lab Bench Work to Its Clinical Perspectives written by Jorge Morales Montor and published by Academic Press. This book was released on 2020-10-01 with total page 288 pages. Available in PDF, EPUB and Kindle. Book excerpt: Immunotherapy in Resistant Cancer: From the Lab Bench Work to Its Clinical Perspectives provides high level knowledge on detailed mechanisms of actions and biological interactions of different immune drugs, with an aim of offering researchers and clinicians cutting-edge therapies to overcome drug resistance. The book explains the latest immunotherapies for different types of cancer, helping users carry out research projects or create alternatives for drug development in the pharmaceutical industry. Topics discussed include the relationship between immunotherapy and macrophages, immune checkpoints in different types of cancer, immune cocktails in solid tumors, and immune-phenotyping. Additionally, the book presents basic and clinical data on immunoresistance and glycosylation. This book is a valuable source for cancer researchers, medical doctors, clinicians and members of the biomedical field who must understand certain mechanisms to fight cancer that is resistant to immunotherapy. Provides basic and clinical evidence based on molecular interactions and clinical studies to address the risks and benefits of cancer immunotherapy Presents the results of new immunotherapy trials, discussing the state-of-the-art in different types of cancer Discusses targeted therapies approved by the FDA, along with therapies with clinical potential used in basic studies
Download or read book Characterization of Cytotoxic T Lymphocyte Mediated Immunotherapy Tolerant Cancer Persister Cells written by Filipe Araujo Hoffmann and published by . This book was released on 2021 with total page 50 pages. Available in PDF, EPUB and Kindle. Book excerpt: Following initial therapy responses, tumors often relapse leading to patient mortality. How cancer cells change from a therapy sensitive to a therapy resistant state is poorly understood, particularly in the context of cytotoxic CD8 T cells mediated immunotherapy. Multiple studies have identified mechanisms by which residual tumor cells avoid CD8 T cell activation, but thus far there have been no studies focused on whether residual tumor cells survive continuous exposure to and attack by activated CD8 T cells. We hypothesized that in addition to commonly proposed evasive mechanisms, cancer cells can enter an immunotherapy-tolerant persister cell state to survive activated CD8 T cell attack. Here, we report the observation of a subpopulation of quiescent immunotherapy persister cells which survive through a reversible, non-genetic mechanism. Upon extended cytotoxic T cell pressure, a subset of immunotherapy persister cells reenter the cell cycle and regrow into overtly resistant colonies which may represent the initial events of acquired resistance and tumor recurrence. These findings suggest that cancer cells may survive initial T cell cytotoxicity exposure through a quiescent persister state for several weeks prior to relapse. Interestingly, we found that immunotherapy persister cells survive despite continual T cell activation and experience sublethal activation of apoptotic signaling. Together, these studies reveal a novel population of tumor cells which survive extended CD8 T cell attack and may seed tumor recurrence during acquired resistance to immunotherapy.
Download or read book Novel Strategies for Cancer Immunotherapy Targeting Immune Mediated Suppressive Mechanisms written by Virginie Lafont and published by Frontiers Media SA. This book was released on 2021-07-02 with total page 182 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Cancer Immunology Innovative Approaches to Therapy written by Ronald B. Herberman and published by Springer Science & Business Media. This book was released on 1986-02-28 with total page 250 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume is the second in the 'Cancer Treatment and Research' series focussing on basic and clinical tumor immunology. It has a rather different focus or emphasis from that of the first volume, published two years ago. That work (Basic and Clinical Tumor Immunology, R.B. Herberman, ed., Martinus Nijhoff Publishers, 1983) devoted considerable attention to up dated summaries in various areas of classical tumor immunology: specific antitumor immunity, the immunologic competence of cancer patietns, char acterization of human tumor-associated antigens, the ability to propagate specifically immune T cells in culture in the presence of interleukin 2, and the use of such cells for adoptive immunotherapy of established tumors. of evidence concerning the immune However, it also reviewed the status surveillance hypothesis and pointed out the need to consider non-T cell mediated mechanisms of host resistance. In particular, one chapter sum marized information on the role of macrophages in host resistance against tumors. The present volume continues to emphasize one of the major themes of the first volume, innovative approaches to the therapy of cancer. It involves contributions from leading investigators on several primary types of therapeutic interventions related to monoclonal antibodies, the col laboration of monoclonal antibodies with macro phages to mediate antibody dependent cellular cytotoxicity, lymphokines, tumor vaccines, and natural killer cells. It also has an up-to-date summary of the immunologic aspects of the exciting and promising work being performed on human T cell leukemia virus in the laboratory of Dr. Robert Gallo.
Download or read book Oncoimmunology written by Laurence Zitvogel and published by Springer. This book was released on 2017-12-13 with total page 700 pages. Available in PDF, EPUB and Kindle. Book excerpt: In this book, leading experts in cancer immunotherapy join forces to provide a comprehensive guide that sets out the main principles of oncoimmunology and examines the latest advances and their implications for clinical practice, focusing in particular on drugs with FDA/EMA approvals and breakthrough status. The aim is to deliver a landmark educational tool that will serve as the definitive reference for MD and PhD students while also meeting the needs of established researchers and healthcare professionals. Immunotherapy-based approaches are now inducing long-lasting clinical responses across multiple histological types of neoplasia, in previously difficult-to-treat metastatic cancers. The future challenges for oncologists are to understand and exploit the cellular and molecular components of complex immune networks, to optimize combinatorial regimens, to avoid immune-related side effects, and to plan immunomonitoring studies for biomarker discovery. The editors hope that this book will guide future and established health professionals toward the effective application of cancer immunology and immunotherapy and contribute significantly to further progress in the field.
Download or read book Tumor Immunology and Immunotherapy written by Robert C. Rees and published by OUP Oxford. This book was released on 2014-05-29 with total page 496 pages. Available in PDF, EPUB and Kindle. Book excerpt: Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers. BCG immunotherapy is now being used as a first line treatment for human bladder cancer and the introduction of prophylactic vaccination against Hepatitis B and HPV cancers is starting to show positive results. Following recent FDA approval for a vaccination against prostate cancer, and optimistic results in clinical trials for a vaccine targeting cancer antigens in lung cancer, cancer immunotherapy is now significantly impacting patient clinical management. Tumor Immunology and Immunotherapy provides an up-to-date and comprehensive account of cancer immunity and immunotherapy. It discusses our adaptive and innate immunity to cancer, the mechanisms underpinning our immune response, current approaches to cancer immunotherapy, and how tumour and host responses can circumvent effective anti-cancer immunity. The book examines recent results, publications and current areas of interest including 'immune editing' and the specific issues that are affecting the research and development of vaccines, providing insight into how these problems may be overcome, as viewed by world leaders in the field. Tumor Immunology and Immunotherapy will appeal to clinicians working in oncology and cancer immunotherapy, and research scientists including PhD and masters students, post-doctoral researchers and senior investigators.
Download or read book Cancer Immunotherapy Principles and Practice Second Edition written by Lisa H. Butterfield, PhD and published by Springer Publishing Company. This book was released on 2021-08-25 with total page 1339 pages. Available in PDF, EPUB and Kindle. Book excerpt: Thoroughly updated to reflect major advances in the field of immuno-oncology, this second edition of Cancer Immunotherapy Principles and Practice, from the Society for Immunotherapy of Cancer (SITC), remains the definitive resource for information on tumor immunology and cancer immunotherapy treatments. An essential reference for both novice and experienced cancer researchers, oncologists, and related practitioners alike, the book not only guides readers through the fundamental scientific principles of the field all the way to translational and practical clinical applications for treating and managing oncologic disease, but also provides a comprehensive understanding of the regulatory processes that support the safe and effective delivery of immunotherapy to patients with cancer. The expanded and updated second edition now spans 68 chapters, including 12 new chapters, covering major topics and innovations that have shaped the rapid development of immunotherapy and its ascension into the standard of care as first-line treatment for a growing number of disease settings. New to this edition are chapters with deeper insight into our understanding of cancer genomics and determinants of response, immunogenic cell death, cancer and stromal cell-intrinsic pathways of immune resistance, cancer immune exclusion, adoptive cell therapy, metabolomics, tumor mutation burden, immunotherapy in combination with radiation therapy, synthetic biology, and more. Complete with detailed illustrations, tables, and key points for targeted reference, Cancer Immunotherapy Principles and Practice, Second Edition is the most comprehensive and authoritative resource for scientists and clinicians looking to expand their knowledge base of this dynamic field. Key Features: Offers key insights and perspectives on cancer immunology and immunotherapy treatments from renowned experts in the field Covers the basic principles and science behind cancer immunotherapy and tumor immunology Includes treatment strategies for a vast array of available immunotherapy classes and agents, such as cytokine therapies, oncolytic viruses, cancer vaccines, CAR T therapies, and combination immunotherapies Provides essential information on FDA-approved immunotherapies, including clinical management and outcome data related to response rates, risks, and toxicities Discusses special considerations for immunotherapy in the context of specific disease settings, including skin cancers, genitourinary cancers, gastrointestinal cancers, hepatocellular carcinomas, gynecologic malignancies, breast cancers, lung cancers, head and neck cancers, brain tumors, sarcomas, pediatric cancers, and treatments combined with radiation therapy Clarifies the complex regulatory aspects behind the development and approval of immunotherapy drugs
Download or read book Cancer Immunotherapy written by Davide Bedognetti and published by Elsevier Inc. Chapters. This book was released on 2013-06-04 with total page 43 pages. Available in PDF, EPUB and Kindle. Book excerpt: During the last few years several immunotherapies have been shown to induce clinical response and/or improve the clinical outcome in a significant number of cancer patients. However, the lack of a human-centered translational approach has led to the accumulation of a multitude of disjointed clinical and basic researches with a consequent disharmonic growth of the scientific knowledge. The huge number of non-evidence-based conjectural hypotheses has competitively interacted with the few evidence-based hypotheses generated by studies conducted in humans leading to the accumulation of several clinical breakdowns and few “mysterious” successes. In the last decade, the availability of high-throughput gene expression profiling has led to the development of novel discovery-driven approaches capable of investigating the tumor/host integration in its globality. Here, we describe in detail gene expression profiling studies that have led to the formulation of a new generation of evidence-based hypotheses explaining the structural basis of the immune-mediated tumor rejection following immunotherapy.
Download or read book Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy written by Emmanuel Donnadieu and published by Springer. This book was released on 2016-08-30 with total page 202 pages. Available in PDF, EPUB and Kindle. Book excerpt: This volume focuses on recent advances in understanding T cells as key players in antitumor immune responses, and as a result T cell-based immunotherapy is starting to transform the treatment of advanced cancers. However, despite recent successes, many patients with cancer fail to respond to these treatments. Defective migration of T cells into and within tumors is considered as an important resistance mechanism to cancer immunotherapy.The volume includes three sections. The first section covers general knowledge about T cell trafficking during a normal immune response but also during tumor development. The second section provides an in-depth description of the different obstacles that prevent T cells from migrating and contacting tumor cells. The third section explores therapeutic strategies to improve trafficking of T cells into tumors and, thus, to enhance the effectiveness of cancer immunotherapy.
Download or read book MHC Class I Loss and Cancer Immune Escape written by Federico Garrido and published by Springer. This book was released on 2019-05-28 with total page 101 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book is about the escape strategies used by cancer cells to avoid the immune response of the host. The main characters of this story are the “Antigen Presenting Molecules” and the “T Lymphocytes”. The former are known as the Major Histocompatibility Complex (MHC): the H-2 and the HLA molecules. The latter are a subgroup of white cells travelling all over our body which are capable to distinguish between “self and non self”. Readers will know from the inside about the history of the HLA genetic system and will discover how T lymphocytes recognize and destroy cancer cells. One of the key important questions is: Why tumors arise, develop and metastasize? This book tries to answer this question and will explain how cancer cells become invisible to killer T lymphocytes. The loss of the HLA molecules is a major player in this tumor escape mechanism. Cancer immunotherapy is aimed at stimulating T lymphocytes to destroy tumor cells. However, the clinical response rate is not as high as expected. The molecular mechanisms responsible for MHC/HLA antigen loss play a crucial role in this resistance to immunotherapy. This immune escape mechanism will be discussed in different types of tumors: lung, prostate, bladder and breast...ect. as well as melanoma and lymphoma. This book will be useful to Oncologists, Pathologists and Immunologist that will enter this fascinating area of research. It will be also interesting for biologist, doctoral students and medical residents interested in “Tumor Immunology”.
Download or read book Lymphocytes in Immunotherapy of Cancer written by Paul Koldovsky and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 171 pages. Available in PDF, EPUB and Kindle. Book excerpt: In the past, research in cancer immunology has produced informa tion important for other medical disciplines. It helped, for example, in formulating the laws of immunogenetics and in achieving a better understanding of the mechanism governing the fate of allotrans planted tissue. Cancer has often been considered a foreign body, and therefore many attempts have been made to cure it on the basis of the immunological principles applicable to parasitic, bacterial, or viral diseases. Vaccination has been investigated clinically for its po tential to prevent cancer [1], and clinical research into the cure of cancer has included active immunization [2], nonspecific stimulation of defense mechanisms [3], and transfer of passive immunity by cells [4] or by antibodies [5]. These experiments have been of limited value and in some cases have even had an adverse effect. The reputation of cancer immunology has suffered, and the concept has often been severely criticized. However, the basic postulate that cancer must originate from the body's own cells, and that the immune system belongs to the principal regulatory mechanisms, remains valid. In recent years new research into clinical cancer immunotherapy has included critical appraisal of all its potential benefits, and also of the risks and limitations. It is dangerous to make unrealistic promises or to speak or think in terms of "miracle weapons" or a "magic bul let.
Download or read book Immunological Surveillance written by Macfarlane Burnet and published by Elsevier. This book was released on 2014-05-17 with total page 289 pages. Available in PDF, EPUB and Kindle. Book excerpt: Immunological Surveillance
Download or read book Cancer Immunology and Immunotherapy written by Mansoor M. Amiji and published by Elsevier. This book was released on 2021-08-27 with total page 548 pages. Available in PDF, EPUB and Kindle. Book excerpt: Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy examines the challenges of delivering immuno-oncology therapies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. Nanotechnology-based targeted delivery strategies could improve the delivery efficiency of IO agents as well as provide additional avenues for novel therapeutic and vaccination strategies. Additionally, a number of locally-administered immunogenic scaffolds and therapeutic strategies, such as the use of STING agonist, could benefit from rationally designed biomaterials and delivery approaches. Delivery Technologies for Immuno-Oncology: Volume 1: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side. Comprehensive treaty covering all aspects of immuno-oncology (IO) Novel strategies for delivery of IO therapeutics and vaccines Forecasting on the future of nanotechnology and drug delivery for IO
Download or read book Principles of Immunotherapy in Breast and Gastrointestinal Cancers written by Michele Ghidini and published by Elsevier. This book was released on 2024-09-05 with total page 206 pages. Available in PDF, EPUB and Kindle. Book excerpt: Principles of Immunotherapy in Breast and Gastrointestinal Cancers: Activity, Mechanisms of Resistance and New Sensitization Strategies presents updated research findings on immunotherapy, with special focus on the mechanisms of resistance of those cancer types and how to overcome them. The book discusses topics such as tumor cell-intrinsic and extrinsic mechanisms of cancer resistance to immunotherapy; the role of currently available biomarkers; strategies to overcome therapeutic resistance; sensitizing agents for cancer resistance to cell mediated immunotherapy; and Immunotherapeutic approaches, mechanisms of resistance and sensitizing strategies in gastroesophageal and biliopancreatic tumors and colorectal cancer. It is a valuable resource for researchers, students and members of the biomedical and medical fields who want to learn more about resistance to immunotherapy and how to overcome it. Presents relevant findings on immunotherapy for breast and GI cancer types in a synthetic and didactic way for easy consult Describes resistance mechanisms of those cancer types and how to overcome them to improve immunotherapy outcomes Encompasses several diagrams and figures to help readers get a clearer picture of the research findings and how they can be applied to the clinical setting
Download or read book Cancer Immunotherapy at the Crossroads written by James H. Finke and published by Springer Science & Business Media. This book was released on 2004 with total page 416 pages. Available in PDF, EPUB and Kindle. Book excerpt: Leading investigators and clinicians detail the different mechanisms used by tumors to escape and impair the immune system and then spell out possible clinical strategies to prevent or reverse tumor-induced immune dysfunction. The authors review the mechanisms of immune dysfunction and evasion mechanisms in histologically diverse human tumors, focusing on tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that may serve as biomarkers for patient prognosis. Cutting-edge techniques are out-lined with the capacity to monitor the strength and quality of patients' immune responses using immunocytometry, MHC-peptide tetramers combined with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.
Download or read book Regulation of Cancer Immune Checkpoints written by and published by . This book was released on 2020 with total page 657 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book systematically reviews the most important findings on cancer immune checkpoints, sharing essential insights into this rapidly evolving yet largely unexplored research topic. The past decade has seen major advances in cancer immune checkpoint therapy, which has demonstrated impressive clinical benefits. The family of checkpoints for mediating cancer immune evasion now includes CTLA-4, PD-1/PD-L1, CD27/CD70, FGL-1/LAG-3, Siglec-15, VISTA (PD-1L)/VSIG3, CD47/SIRPA, APOE/LILRB4, TIGIT, and many others. Despite these strides, most patients do not show lasting remission, and some cancers have been completely resistant to the therapy. The potentially lethal adverse effects of checkpoint blockade represent another major challenge, the mechanisms of which remain poorly understood. Compared to the cancer signaling pathways, such as p53 and Ras, mechanistic studies on immune checkpoint pathways are still in their infancy. To improve the responses to checkpoint blockade therapy and limit the adverse effects, it is essential to understand the molecular regulation of checkpoint molecules in both malignant and healthy cells/tissues. This book begins with an introduction to immune checkpoint therapy and its challenges, and subsequently describes the regulation of checkpoints at different levels. In closing, it discusses recent therapeutic developments based on mechanistic findings, and outlines goals for future translational studies. The book offers a valuable resource for researchers in the cancer immunotherapy field, helping to form a roadmap for checkpoint regulation and develop safer and more effective immunotherapies.